PARP Inhibitor Alone or Plus Immunotherapy for Advanced BRCA-Associated Breast Cancer
Clinicaltrials.gov identifier:
NCT02849496
Study Contact Information:
For additional information, please contact: Jamison Langguth by phone at: 203-4647261 or by email.
A Study in Advanced Breast Cancer Patients with BRCA 1/2 Mutations Evaluating Olaparib alone or in Combination with Atezolizumab
About the Study
This is a study for women or men who have been diagnosed with advanced breast cancer with a 1/2 mutation. The goal of this study is to look at whether giving the damage repair inhibitor () (Lynparza) in combination with the atezolizumab (Tecentriq) improves outcomes for patients compared to alone. NOTE: This study is no longer enrolling people.
NOTE: This study is no longer enrolling people.
NOTE: This study is no longer enrolling people.